Avalon GloboCare (ALBT) Competitors $5.27 -0.05 (-0.94%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$5.31 +0.04 (+0.76%) As of 03/28/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALBT vs. LSTA, NNVC, BIVI, EGRX, LSB, LPCN, MTEX, SNTI, CGTX, and INABShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Lisata Therapeutics (LSTA), NanoViricides (NNVC), BioVie (BIVI), Eagle Pharmaceuticals (EGRX), Lakeshore Biopharma (LSB), Lipocine (LPCN), Mannatech (MTEX), Senti Biosciences (SNTI), Cognition Therapeutics (CGTX), and IN8bio (INAB). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. Lisata Therapeutics NanoViricides BioVie Eagle Pharmaceuticals Lakeshore Biopharma Lipocine Mannatech Senti Biosciences Cognition Therapeutics IN8bio Lisata Therapeutics (NASDAQ:LSTA) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation. Is LSTA or ALBT more profitable? Lisata Therapeutics has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,125.59%. Avalon GloboCare's return on equity of 0.00% beat Lisata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lisata TherapeuticsN/A -51.19% -45.16% Avalon GloboCare -1,125.59%N/A -73.69% Which has preferable valuation and earnings, LSTA or ALBT? Avalon GloboCare has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLisata Therapeutics$1M20.26-$20.84M-$2.40-0.98Avalon GloboCare$1.31M4.40-$16.71M-$19.96-0.26 Does the MarketBeat Community believe in LSTA or ALBT? Lisata Therapeutics received 14 more outperform votes than Avalon GloboCare when rated by MarketBeat users. CompanyUnderperformOutperformLisata TherapeuticsOutperform Votes1493.33% Underperform Votes16.67%Avalon GloboCareN/AN/A Do institutionals & insiders hold more shares of LSTA or ALBT? 8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 37.3% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer LSTA or ALBT? Lisata Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 538.30%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Lisata Therapeutics is more favorable than Avalon GloboCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Avalon GloboCare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, LSTA or ALBT? Lisata Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500. Does the media prefer LSTA or ALBT? In the previous week, Avalon GloboCare had 1 more articles in the media than Lisata Therapeutics. MarketBeat recorded 3 mentions for Avalon GloboCare and 2 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.43 beat Avalon GloboCare's score of 1.12 indicating that Lisata Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Lisata Therapeutics Positive Avalon GloboCare Positive SummaryLisata Therapeutics beats Avalon GloboCare on 11 of the 17 factors compared between the two stocks. Remove Ads Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.77M$3.03B$5.63B$7.83BDividend YieldN/A1.56%4.57%4.00%P/E Ratio-0.2628.9323.3318.67Price / Sales4.40429.70388.4691.01Price / CashN/A168.6838.1634.64Price / Book-0.313.926.894.23Net Income-$16.71M-$71.95M$3.20B$247.15M7 Day Performance-16.22%-5.60%-3.02%-2.17%1 Month Performance-27.31%-11.96%1.63%-5.68%1 Year Performance9.79%-28.47%9.74%-0.67% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare2.1467 of 5 stars$5.27-0.9%N/A+9.8%$5.77M$1.31M-0.265Short Interest ↓LSTALisata Therapeutics3.0246 of 5 stars$2.38-0.4%$15.00+530.3%-24.7%$20.52M$1M-0.9530Short Interest ↓Gap DownNNVCNanoViricidesN/A$1.31+6.5%N/A+4.3%$20.49MN/A-1.8220News CoverageBIVIBioVie2.8379 of 5 stars$1.10+1.9%$3.00+172.7%+91.1%$20.30MN/A-0.1110Short Interest ↓News CoveragePositive NewsEGRXEagle PharmaceuticalsN/A$1.50+15.4%N/A-83.2%$19.48M$257.55M0.00100Gap DownLSBLakeshore Biopharma1.5046 of 5 stars$2.05+2.3%N/AN/A$19.03M$672.27M0.00773Positive NewsLPCNLipocine2.0897 of 5 stars$3.50+4.5%$10.00+185.7%-36.9%$18.72M$7.92M-4.6110MTEXMannatech0.5306 of 5 stars$9.92-3.0%N/A+3.3%$18.70M$121.55M-12.25250Earnings ReportAnalyst ForecastGap DownSNTISenti Biosciences3.4634 of 5 stars$3.87+10.9%$10.00+158.4%-9.0%$18.69M$2.56M-0.254Short Interest ↓Gap UpCGTXCognition Therapeutics3.7278 of 5 stars$0.45-0.1%$8.30+1,757.2%-77.2%$18.57MN/A-0.4620Short Interest ↓Analyst RevisionINABIN8bio3.054 of 5 stars$0.23+0.4%$6.75+2,884.1%-83.4%$18.38MN/A-0.3020Short Interest ↑ Remove Ads Related Companies and Tools Related Companies Lisata Therapeutics Competitors NanoViricides Competitors BioVie Competitors Eagle Pharmaceuticals Competitors Lakeshore Biopharma Competitors Lipocine Competitors Mannatech Competitors Senti Biosciences Competitors Cognition Therapeutics Competitors IN8bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALBT) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
